The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1748
February 16, 2026
View Complete Issue         Table of Contents 2019 
Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
February 16, 2026 (Issue: 1748)
The FDA has approved Emblaveo (Abbvie), an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with metronidazole to treat complicated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
Article code: 1748a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.